Apitolisib
| Title | Journal |
|---|---|
| Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. | Journal of molecular biology 20170217 |
| Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20121215 |
| Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. | Drug metabolism and disposition: the biological fate of chemicals 20120901 |
| Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. | Molecular cancer therapeutics 20120701 |
| GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. | Molecular cancer therapeutics 20111201 |
| Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. | Journal of medicinal chemistry 20111110 |
| The emerging mechanisms of isoform-specific PI3K signalling. | Nature reviews. Molecular cell biology 20100501 |
| mTOR signaling at a glance. | Journal of cell science 20091015 |
| Defining the role of mTOR in cancer. | Cancer cell 20070701 |
| The phosphoinositide 3-kinase pathway. | Science (New York, N.Y.) 20020531 |
| Screening hospital admissions from the emergency department for occult carbon monoxide poisoning. | The American journal of emergency medicine 19900701 |